SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1741 8267 "

Sökning: L773:1741 8267

  • Resultat 71-80 av 84
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
71.
  • Johansson, SE, et al. (författare)
  • Smokeless tobacco and coronary heart disease: a 12-year follow-up study
  • 2005
  • Ingår i: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. - : Oxford University Press (OUP). - 1741-8267. ; 12:4, s. 387-392
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Cigarette smoking has declined whereas the use of smokeless tobacco is increasing. There is an ongoing debate as to whether smokeless tobacco is a recommendable strategy to help smokers to quit. However, very few studies have examined the association between smokeless tobacco, namely snuff, and coronary heart disease, which implies that it has not been possible to provide scientific results for public health policies and clinical guidelines concerning the use of smokeless tobacco. Design A follow-up study. Methods A random sample of 3120 healthy men aged 30–74 years was interviewed in 1988 and 1989 and followed up to the year 2000 with regard to coronary heart disease. Cox regression was used to estimate the relative risk of coronary heart disease in six categories of smoking and snuffing habits, after adjustment for established risk factors for coronary heart disease. Results Smokers, former smokers, and those who combined smoking and snuffing had significantly higher hazard ratios than never-smokers. The very highest hazard ratio was found among individuals combining smoking and snuffing. Daily snuffers had a hazard ratio of 1.62 (95% confidence interval 0.70–3.03) after adjustment for age. Conclusions Even though the association between daily snuffing and coronary heart disease was non-significant, the hazard ratio was markedly increased. Therefore, smokers should not use smokeless tobacco in order to quit smoking, especially as safer alternatives are available. Further studies in different settings are required to provide scientific results for public health policies and clinical guidelines.
  •  
72.
  •  
73.
  • Lindgren, P., et al. (författare)
  • Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)
  • 2005
  • Ingår i: Eur J Cardiovasc Prev Rehabil. - : Oxford University Press (OUP). - 1741-8267. ; 12:1, s. 29-36
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The aim of this study is to assess the cost-effectiveness of the lipid-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) where patients from seven countries with hypertension and no history of coronary heart disease (CHD) were randomized to receive 10 mg atorvastatin or placebo. DESIGN: Economic analysis of a randomized controlled trial. METHODS: Data on resource use were aggregated for all patients during the entire trial period (median 3.3 years) and multiplied with unit costs for Sweden and the UK. The total number of cardiovascular events and procedures avoided was used as the measure of effectiveness. RESULTS: Patients treated with atorvastatin had an additional net costs of 449 euro (4114 SEK) in Sweden and 414 euro (260 pounds sterling) in the UK, but fewer events per patient (0.097 compared to 0.132). The incremental cost-effectiveness ratios were 12673 euro (116119 SEK) and 11693 euro (7349 pounds sterling) per event avoided. CONCLUSION: Based on comparisons with the WOSCOPS and 4S studies, atorvastatin at 10 mg to treat patients as in the ASCOT study, appears to be a cost-effective strategy.
  •  
74.
  • Olsson, Anders, et al. (författare)
  • LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study
  • 2011
  • Ingår i: EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION and REHABILITATION. - : Lippincott Williams and Wilkins. - 1741-8267. ; 18:2, s. 262-269
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims: We assessed the proportion of patients treated with either simvastatin 20 or 40 mg or atorvastatin 80 mg who achieved low-density lipoprotein cholesterol (LDL-C) goals of 2.5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study. We explored how lipoprotein components related to cardiovascular disease (CVD) outcomes in these groups. Methods and results: For subjects who reached on-treatment LDL-C goals, Cox regression models were used to assess the ability of lipoprotein components to predict CVD events. Treatment with simvastatin or atorvastatin resulted in 40 per cent and 80 per cent of patients, respectively, reaching the 2.5 mmol/l goal and 12 per cent and 52 per cent, respectively, reaching the 2.0 mmol/l goal, after 1 year (all p andlt; 0.001 between groups). Adjusting for baseline LDL-C levels, hazard ratio (HR) for those reaching 2.0-2.5 mmol/l LDL-C versus those reaching andlt; 2.0 mmol/l was 1.16 (95% confidence interval [CI], 1.02-1.33, p = 0.023). An increase of the apolipoprotein B/A1 (apoB/A1) ratio by 1 standard deviation in participants who reached 2.0 mmol/l showed a HR for CVD of 1.14 (95% CI, 1.04-1.25, p = 0.004). Conclusion: More CVD patients treated with atorvastatin than simvastatin achieved either LDL-C goal and those reaching the 2.0 mmol/l goal exhibited significantly less CVD than those only reaching 2.5 mmol/l. In those reaching the 2.0 mmol/l goal, the apoB/A1 ratio still bears a relation to CVD outcome. The use of apoB/A1 ratio may provide additional predictive value to that of LDL-C.
  •  
75.
  • Ryden, L, et al. (författare)
  • The European Heart Health Charter: towards a healthier Europe
  • 2007
  • Ingår i: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. - : Oxford University Press (OUP). - 1741-8267. ; 14:3, s. 355-356
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
76.
  • Shelley, E, et al. (författare)
  • Promoting heart health--a European consensus
  • 2004
  • Ingår i: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. - : Oxford University Press (OUP). - 1741-8267. ; 11:2, s. 85-86
  • Forskningsöversikt (refereegranskat)
  •  
77.
  •  
78.
  •  
79.
  •  
80.
  • Thrainsdottir, IS, et al. (författare)
  • Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavík Study
  • 2005
  • Ingår i: European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. - : Oxford University Press (OUP). - 1741-8267. ; 12:5, s. 465-471
  • Tidskriftsartikel (refereegranskat)abstract
    • The risk of cardiovascular disease increases progressively with increasing blood glucose from levels well below the diabetic threshold. In the Reykjavik Study the relationship between heart failure and abnormal glucose regulation was already apparent at the level of impaired glucose tolerance. The aim of this study was to determine the prognosis of participants with any glucose abnormality and heart failure and to test whether the combination of these conditions may adversely affect the subsequent prognosis. Design A prospective population-based study. Methods Data from the first visit of 19 381 participants were used. Participants were divided into groups according to their glycaemic and heart failure level, and comparisons were made between the groups and disease-free participants serving as a reference group. The risk of mortality and morbidity was calculated with adjustments for main cardiovascular risk factors and ischaemic heart disease. Results Participants in the reference group were younger, had lower body mass indices and more seldom a history of myocardial infarction compared with diseased groups. Mortality was lowest in the reference group ( P < 0.0001) increasing to a maximum in participants with the combination of glucose abnormality and heart failure. Prognostically, the mortality risk associated with abnormal glucose regulation was increased but was lower than the risk of diabetes. The risk of a new myocardial infarction was highest in participants with diabetes [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.3-2.0] or diabetes in combination with heart failure (HR 1.8; CI 1.1-2.7). Conclusions Heart failure or glucose abnormalities are related to increased morbidity and mortality. The combination of glucose abnormality and heart failure did, however, not add further to the unfavourable prognosis in the presence of ischaemic heart disease.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 71-80 av 84
Typ av publikation
tidskriftsartikel (80)
forskningsöversikt (4)
Typ av innehåll
refereegranskat (81)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Rydén, L. (12)
Nilsson, Peter (6)
Boman, Kurt (6)
Wilhelmsen, Lars, 19 ... (5)
Jansson, Jan-Håkan (5)
Rosengren, Annika, 1 ... (4)
visa fler...
Lind, Lars (3)
Hellénius, Mai-Lis (3)
Hallmans, Göran (3)
Lindahl, Bernt (3)
Tuomilehto, J. (3)
Orth-Gomer, K (3)
Sundström, Johan (3)
Weinehall, Lars (3)
Lindgren, Peter (3)
Stahle, A (3)
Anselmino, M (3)
Johansson, Lars (2)
Engström, Gunnar (2)
Hammar, N (2)
Malmberg, K (2)
Collins, R (2)
Stenlund, Hans (2)
Yusuf, S. (2)
Jonsson, B (2)
Holme, Ingar (2)
Zamorano, Jose Luis (2)
Kahan, T (2)
Hedblad, Bo (2)
Cederholm, Jan (2)
Zethelius, Björn (2)
Olsson, Anders (2)
Stegmayr, Birgitta (2)
Ingelsson, Erik (2)
Lindgren, P (2)
Johansson, SE (2)
Thelle, Dag, 1942 (2)
De Backer, G (2)
Sans, S (2)
de Faire, Ulf (2)
Wennberg, Patrik, 19 ... (2)
Ärnlöv, Johan (2)
Michaëlsson, Karl (2)
Wandell, P (2)
Janzon, Lars (2)
Dahlöf, Björn, 1953 (2)
Sans, Susana (2)
Sundquist, J. (2)
Giampaoli, Simona (2)
Kastelein, John J. P ... (2)
visa färre...
Lärosäte
Karolinska Institutet (47)
Uppsala universitet (18)
Umeå universitet (16)
Göteborgs universitet (15)
Lunds universitet (11)
Linköpings universitet (7)
visa fler...
Linnéuniversitetet (3)
Örebro universitet (2)
Gymnastik- och idrottshögskolan (2)
Högskolan Dalarna (2)
Luleå tekniska universitet (1)
Mälardalens universitet (1)
Jönköping University (1)
Mittuniversitetet (1)
Högskolan i Borås (1)
visa färre...
Språk
Engelska (84)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (32)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy